PF 184CAS# 1187460-81-6 |
- Methylcobalamin
Catalog No.:BCC5188
CAS No.:13422-55-4
- Miglustat hydrochloride
Catalog No.:BCC5186
CAS No.:210110-90-0
- Tirapazamine
Catalog No.:BCC5184
CAS No.:27314-97-2
- Amifampridine
Catalog No.:BCC5185
CAS No.:54-96-6
- Miglustat
Catalog No.:BCC5187
CAS No.:72599-27-0
- Grape Seed Extract
Catalog No.:BCC5317
CAS No.:84929-27-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1187460-81-6 | SDF | Download SDF |
| PubChem ID | 57519531 | Appearance | Powder |
| Formula | C32H32ClFN6O4 | M.Wt | 619.09 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO | ||
| Chemical Name | 8-[[2-[(3S,4R)-3,4-bis(hydroxymethyl)-3,4-dimethylpyrrolidin-1-yl]-5-chloropyridine-4-carbonyl]amino]-1-(4-fluorophenyl)-4,5-dihydrobenzo[g]indazole-3-carboxamide | ||
| SMILES | CC1(CN(CC1(C)CO)C2=NC=C(C(=C2)C(=O)NC3=CC4=C(CCC5=C4N(N=C5C(=O)N)C6=CC=C(C=C6)F)C=C3)Cl)CO | ||
| Standard InChIKey | JUOWWGNRWRLBSV-MEKGRNQZSA-N | ||
| Standard InChI | InChI=1S/C32H32ClFN6O4/c1-31(16-41)14-39(15-32(31,2)17-42)26-12-24(25(33)13-36-26)30(44)37-20-7-3-18-4-10-22-27(29(35)43)38-40(28(22)23(18)11-20)21-8-5-19(34)6-9-21/h3,5-9,11-13,41-42H,4,10,14-17H2,1-2H3,(H2,35,43)(H,37,44)/t31-,32+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent and selective IKKβ inhibitor (IC50 = 37 nM). Displays selectivity over 85 other kinases. Inhibits IL-1β-induced TNF-α production in a steroid-insensitive in vitro model of oxidative stress. |
PF 184 Dilution Calculator
PF 184 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.6153 mL | 8.0764 mL | 16.1527 mL | 32.3055 mL | 40.3819 mL |
| 5 mM | 0.3231 mL | 1.6153 mL | 3.2305 mL | 6.4611 mL | 8.0764 mL |
| 10 mM | 0.1615 mL | 0.8076 mL | 1.6153 mL | 3.2305 mL | 4.0382 mL |
| 50 mM | 0.0323 mL | 0.1615 mL | 0.3231 mL | 0.6461 mL | 0.8076 mL |
| 100 mM | 0.0162 mL | 0.0808 mL | 0.1615 mL | 0.3231 mL | 0.4038 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Trametinib DMSO solvate
Catalog No.:BCC2013
CAS No.:1187431-43-1
- Cuniloside B
Catalog No.:BCN6062
CAS No.:1187303-40-7
- Resminostat hydrochloride
Catalog No.:BCC1888
CAS No.:1187075-34-8
- H-Cys(Me)-OH
Catalog No.:BCC2908
CAS No.:1187-84-4
- 11-Hydroxycodaphniphylline
Catalog No.:BCN6061
CAS No.:1186496-68-3
- Evacetrapib (LY2484595)
Catalog No.:BCC2329
CAS No.:1186486-62-3
- TMN 355
Catalog No.:BCC6121
CAS No.:1186372-20-2
- Epivogeloside
Catalog No.:BCN6060
CAS No.:118627-52-4
- 4SC-202
Catalog No.:BCC5359
CAS No.:1186222-89-8
- ALW-II-41-27
Catalog No.:BCC1350
CAS No.:1186206-79-0
- NPE-caged-proton
Catalog No.:BCC7698
CAS No.:1186195-63-0
- MTEP hydrochloride
Catalog No.:BCC1780
CAS No.:1186195-60-7
- Baricitinib (LY3009104, INCB028050)
Catalog No.:BCC2195
CAS No.:1187594-09-7
- Baricitinib phosphate
Catalog No.:BCC1401
CAS No.:1187595-84-1
- Carabrolactone A
Catalog No.:BCN6063
CAS No.:1187925-30-9
- Carabrolactone B
Catalog No.:BCN6064
CAS No.:1187925-31-0
- Diosbulbin I
Catalog No.:BCN6065
CAS No.:1187951-05-8
- Diosbulbin J
Catalog No.:BCN6066
CAS No.:1187951-06-9
- Ac-Leu-OH
Catalog No.:BCC2967
CAS No.:1188-21-2
- ent-14,16-Epoxy-8-pimarene-3,15-diol
Catalog No.:BCN6067
CAS No.:1188281-98-2
- 7-Hydroxydarutigenol
Catalog No.:BCN6068
CAS No.:1188281-99-3
- 9-Hydroxydarutigenol
Catalog No.:BCN6069
CAS No.:1188282-00-9
- 16-O-Acetyldarutigenol
Catalog No.:BCN6070
CAS No.:1188282-01-0
- 15,16-Di-O-acetyldarutoside
Catalog No.:BCN6071
CAS No.:1188282-02-1
Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation.[Pubmed:19478133]
J Pharmacol Exp Ther. 2009 Aug;330(2):377-88.
Nuclear factor-kappaB (NF-kappaB) is one of the major families of transcription factors activated during the inflammatory response in asthma and chronic obstructive pulmonary disease. Inhibitory factor-kappaB kinase 2 (IKK-2) has been shown to play a pivotal role in cytokine-induced NF-kappaB activation in airway epithelium and in disease-relevant cells. Nevertheless, the potential toxicity of specific IKK-2 inhibitors may be unacceptable for oral delivery in chronic obstructive pulmonary disease. Therefore, local delivery to the lungs is an attractive alternative that warrants further exploration. Here, we describe potent and selective small-molecule IKK-2 inhibitors [8-(5-chloro-2-(4-methylpiperazin-1-yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-di hydro-1H-benzo[g]indazole-3-carboxamide (PHA-408) and 8-(2-(3,4-bis(hydroxymethyl)-3,4-dimethylpyrrolidin-1-yl)-5-chloroisonicotinamido )-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo-[g]indazole-3-carboxamide (PF-184)] that are competitive for ATP have slow off-rates from IKK-2 and display broad in vitro anti-inflammatory activities resulting from NF-kappaB pathway inhibition. Notably, PF-184 has been designed to have high systemic clearance, which limits systemic exposure and maximizes the effects locally in the airways. We used an inhaled lipopolysaccharide-induced rat model of neutrophilia to address whether inhibiting NF-kappaB activation locally within the airways would show anti-inflammatory effects in the absence of systemic exposure. PHA-408, a low-clearance compound previously shown to be efficacious orally in a rodent model of arthritis, dose-dependently attenuated inhaled lipopolysaccharide-induced cell infiltration and cytokine production. Interestingly, PF-184 produced comparable dose-dependent anti-inflammatory activity by intratracheal administration and was as efficacious as intratracheally administered fluticasone propionate (fluticasone). Together, these results support the potential therapeutic utility of IKK-2 inhibition in inflammatory pulmonary diseases and demonstrate anti-inflammatory efficacy of an inhaled IKK-2 inhibitor in a rat airway model of neutrophilia.
